News

Findings of a new study from the University of Wisconsin-Madison’s Waisman Center investigating the link between a protein typically associated with Alzheimer’s disease, are revealing more information about the earliest stages of the neurodegenerative disease and that this protein’s impact on memory and cognition may not be as clear…

A research project designed to create a molecular map with thousands of proteins in the brain with Alzheimer’s disease, conducted by Dr. Richard Unwin, from The University of Manchester and Central Manchester University Hospitals NHS Foundation Trust has been granted a £30,000 ($48,600 dollars) award by Alzheimer’s Research UK. The…

A novel, wearable sensor system created for dementia patients helps to keep them safe when they wander out of bed during the night while also providing relief to their families and caregivers. The system, which connects to a smartphone, is not only innovative, but is also…

Experts from around the globe gathered in Toronto last week to discuss new approaches to the challenge increasing rates dementia present at an Organization for Economic Co-operation and Development (OECD) workshop organized in partnership with the Ontario Brain Institute (OBI) and the Institute of Health Policy, Management…

Pennsylvania-based Representative Chaka Fattah — a U.S. Congressman behind the Fattah Neuroscience Initiative, which aims to drive collaborative Federal research on brain cognition, development, disease and injury — recently had a meeting with World Dementia Envoy and head of the World Dementia Council, Dr. Dennis Gillings, to…

AstraZeneca and Eli Lilly and Company have reached an agreement for the development and commercialization of the oral beta secretes cleaving enzyme (BACE) inhibitor, AZD3293, which might become a viable treatment for Alzheimer’s disease. The oral therapy is expected to prevent the formation of…

Avanir Pharmaceuticals Inc. reported today new, positive results for their leading drug, AVP-923, designed to treat agitation in Alzheimer’s disease patients. The results will be presented at the American Neurological Association’s (ANA) 2014 Annual Meeting in Baltimore, MD, October 12-14, 2014. Joao Siffert, MD, chief medical officer at Avanir,…

The human brain has the plasticity to compensate for the accumulation of the protein beta-amyloid that causes Alzheimer’s disease, which explains that some individuals develop it and others don’t, as concluded by research conducted at the University of California in Berkeley (UC Berkeley). The researchers analyzed adults with and without beta-amyloid deposits…

A Phase 2 randomized, double blind, placebo-controlled, parallel group study is currently enrolling at multiple test centers in the United States to evaluate the efficacy and safety of T-817MA as a potential treatment in patients with mild to moderate Alzheimer’s disease. This study is a joint phase II clinical…

A new Open Access study published in the prestigious BMJ journal finds indication that use of benzodiazepines, widely prescribed drugs for treatment of anxiety and insomnia, is associated with an increased risk of developing Alzheimer’s disease, particularly for long-term users. These drugs, medically referred to as benzodiazepine receptor agonists,…